Novo Nordisk's ZEUS trial outcome will not impact the company's 2026 adjusted operating profit outlook but will result in a non-cash Q3 2026 impairment charge.
FirstSquawk07/31, 06:23 PM
Related assets
Coming up for NOVO
Explore next
Latest NOVO news
Finnhub08/19, 05:10 PM
FirstSquawk08/04, 11:41 PM
FirstSquawk08/04, 11:41 PM